Project Details
Description
Phase II randomized study of pembrolizumab with or without epigenetic modulation with CC-486 in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
| Status | Finished |
|---|---|
| Effective start/end date | 12/1/16 → 6/30/22 |
Funding
- TRANSLATIONAL RESEARCH IN ONCOLOGY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.